Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
1.
J Appl Physiol (1985) ; 133(6): 1295-1299, 2022 Dec 01.
Article in English | MEDLINE | ID: covidwho-2088959

ABSTRACT

Throughout the COVID-19 pandemic, a portion of those affected have evolved toward acute hypoxic respiratory failure. Initially, this was hypothesized to result from acute lung injury leading to acute respiratory distress syndrome (ARDS). In previous research, a novel quantitative CT post-processing technique was described to quantify the volume of blood contained within pulmonary blood vessels of a given size. We hypothesized that patients with lower BV5 blood flow would have higher supplemental oxygen needs and less favorable arterial blood gas profiles. From the initial data analysis, 111 hospitalized COVID-19 patients were retrospectively selected based on the availability of CT scans of the lungs with a slice thickness of 1.5 mm or less, as well as PCR-confirmed SARS-CoV2 infection. Three-dimensional (3-D) reconstructions of the lungs and pulmonary vasculature were created. Further analysis was performed on 50 patients. Patients were divided into groups based on their need for oxygen at the time of CT scan acquisition. Eighteen out of 50 patients needed >2 L/min supplemental oxygen and this group demonstrated a significantly lower median percentage of total blood flow in the BV5 vessels compared with the 32 patients who needed <2 L/min supplemental oxygen (41.61% vs. 46.89%, P = 0.023). Both groups had significantly less blood as a proportion in BV5 vessels compared with healthy volunteers. These data are consistent with the hypothesis that reduced blood volume within small (BV5) pulmonary vessels is associated with higher needs for supplemental oxygen and more severe gas exchange anomalies in COVID-19 infections.NEW & NOTEWORTHY This research provides, by using new imaging analysis on CT imaging, an insight into the pathophysiology of patients with COVID-19 infection. By visualizing and quantifying the blood in small vessels in the lung, we can link these results to the clinical need for oxygen in patients with COVID-19 infection.


Subject(s)
COVID-19 , Respiratory Distress Syndrome , Humans , Pandemics , SARS-CoV-2 , RNA, Viral , Retrospective Studies , Lung/diagnostic imaging , Respiratory Distress Syndrome/therapy , Tomography, X-Ray Computed/methods , Oxygen , Blood Volume
2.
Thorax ; 76(2): 182-184, 2021 02.
Article in English | MEDLINE | ID: covidwho-733132

ABSTRACT

An increasing observation is that some patients with COVID-19 have normal lung compliance but significant hypoxaemia different from typical acute respiratory distress syndrome (ARDS). We hypothesised that changes in pulmonary blood distribution may be partially responsible and used functional respiratory imaging on CT scans to calculate pulmonary blood volume. We found that patients with COVID-19 had significantly reduced blood volume in the smaller calibre blood vessels (here defined as <5 mm2 cross-sectional area) compared with matched ARDS patients and healthy controls. This suggests that using high levels of PEEP may not alone be enough to oxygenate these patients and that additional management strategies may be needed.


Subject(s)
COVID-19/physiopathology , Lung Compliance/physiology , Lung/physiopathology , Pulmonary Circulation/physiology , Respiratory Mechanics/physiology , SARS-CoV-2 , COVID-19/diagnosis , COVID-19/epidemiology , Humans , Pandemics , Respiratory Function Tests , Retrospective Studies , Tomography, X-Ray Computed
3.
Acad Radiol ; 27(10): 1449-1455, 2020 10.
Article in English | MEDLINE | ID: covidwho-679392

ABSTRACT

RATIONALE AND OBJECTIVES: Mounting evidence supports the role of pulmonary hemodynamic alternations in the pathogenesis of COVID-19. Previous studies have demonstrated that changes in pulmonary blood volumes measured on computed tomography (CT) are associated with histopathological markers of pulmonary vascular pruning, suggesting that quantitative CT analysis may eventually be useful in the assessment pulmonary vascular dysfunction more broadly. MATERIALS AND METHODS: Building upon previous work, automated quantitative CT measures of small blood vessel volume and pulmonary vascular density were developed. Scans from 103 COVID-19 patients and 107 healthy volunteers were analyzed and their results compared, with comparisons made both on lobar and global levels. RESULTS: Compared to healthy volunteers, COVID-19 patients showed significant reduction in BV5 (pulmonary blood volume contained in blood vessels of <5 mm2) expressed as BV5/(total pulmonary blood volume; p < 0.0001), and significant increases in BV5-10 and BV 10 (pulmonary blood volumes contained in vessels between 5 and 10 mm2 and above 10 mm2, respectively, p < 0.0001). These changes were consistent across lobes. CONCLUSION: COVID-19 patients display striking anomalies in the distribution of blood volume within the pulmonary vascular tree, consistent with increased pulmonary vasculature resistance in the pulmonary vessels below the resolution of CT.


Subject(s)
Betacoronavirus , Coronavirus Infections , Lung , Pandemics , Pneumonia, Viral , COVID-19 , Female , Humans , Male , Middle Aged , SARS-CoV-2 , Tomography, X-Ray Computed
4.
EU Clinical Trials Register; 04/06/2020; TrialID: EUCTR2020-002394-94-BE
Clinical Trial Register | ICTRP | ID: ictrp-EUCTR2020-002394-94-BE

ABSTRACT

Condition:

Corona virus disease
MedDRA version: 23.0 Level: LLT Classification code 10084355 Term: COVID-19 virus test positive System Organ Class: 100000004848
MedDRA version: 23.0 Level: LLT Classification code 10084383 Term: Novel COVID-19-infected pneumonia System Organ Class: 100000004862
MedDRA version: 23.0 Level: LLT Classification code 10084401 Term: COVID-19 respiratory infection System Organ Class: 100000004862 ;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]

Intervention:


Product Name: iNO
Pharmaceutical Form: Pressurised inhalation



Primary outcome:

Main Objective: The objective of this study is to examine the utility of high resolution
computed tomography (HRCT) to measure changes in functional
pulmonary imaging parameters as a function of iNO administration using
the device INOpulse in relation to the corona virus disease. Changes
from baseling to at least 5 minutes of iNO and after 5 days using iNO 8 to
24 h/day.
Clinical evaluation of INOpulse for patients with COVID-19 using clinical
and imaging endpoints;Secondary Objective: Not applicable;Primary end point(s): Clinical evaluation of INOpulse for patients with COVID-19 using clinical
1. Death
2. Hospitalized, requiring mechanical ventilation or ECMO
3. Hospitalized, requiring non-invasive ventilation or high flow oxygen
4. Hospitalized, requiring supplemental oxygen
5. Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise)
6. Hospitalized, not requiring supplemental oxygen - not requiring ongoing medical care (COVID-19 related or otherwise)
7. Not hospitalized - limitation on activities and/or requiring home oxygen
8. Not hospitalized, no limitations on activities;Timepoint(s) of evaluation of this end point: Assessed at the start of iNOpulse treatment,during treatment, upon completion of treatment and at follow up (Day 28).

Criteria:

Inclusion criteria:
1. Signed Informed Consent Form (and assent as appropriate) prior to
the initiation of any study mandated procedures or assessments.
2. At least 18 years old
3. Hospitalized patients with proven or high suspicion of SARS-CoV-2
infection and on supplemental oxygen >2 L/minute and = 10 L/minute
4. Suspected or proven pneumonia on chest imaging
5. Female patients of childbearing potential must have a negative pretreatment
pregnancy test (serum or urine). All female patients should
take adequate precaution to avoid pregnancy.
6. Willing and able to comply with treatment schedule and study
procedures.
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 3
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 3


Exclusion criteria:
1. Participating in any other clinical trial of an experimental treatment
for COVID-19
2. Gas exchange and ventilation requiring the use of any continuous
positive airway pressure (CPAP), or any system of Non Invasive
Ventilation (NIV), with Positive End-Expiratory Pressure (PEEP) = 10
cmH2O prior to initiation of iNO
3. Pregnancy, or positive pregnancy test in a pre-dose examination
4. Open tracheostomy
5. Clinical contra-indication, as deemed by the attending physician including chronic lung disease
6. Use of a nitric oxide donor agent such as nitroglycerin or drugs
known to increase methemoglobin such as lidocaine, prilocaine,
benzocaine or dapsone at screening
7. Known history or clinical evidence of heart failure, left ventricular
dysfunction (LVEF < 40 %)
8. Patients reporting hemoptysis

SELECTION OF CITATIONS
SEARCH DETAIL